Romlusevimab

罗米司韦单抗

Report date: 2025/04/11 10:48:12

Base Information

Drug NameRomlusevimab
Drug Alias NameBRII-198BRII198
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2021/12/08
Country/TerritoryCanadaUnited StatesSingapore +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBrii Biosciences (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBrii Biosciences (Shanghai) Co LtdChina Resources Pharmaceutical Commercial Group Co LtdBrii Biosciences (Beijing) Co Ltd +[4] 
Inactive CompaniesBrii Biosciences Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A